Onsdag 30 Oktober | 09:26:46 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2024-11-01 07:00 Kvartalsrapport 2024-Q3
2024-09-09 - X-dag ordinarie utdelning AKBM 45.00 NOK
2024-09-03 - Extra Bolagsstämma 2024
2024-07-12 - Kvartalsrapport 2024-Q2
2024-04-26 - Kvartalsrapport 2024-Q1
2024-04-17 - X-dag ordinarie utdelning AKBM 0.00 NOK
2024-04-16 - Årsstämma
2024-02-14 - Bokslutskommuniké 2023
2023-11-01 - Kvartalsrapport 2023-Q3
2023-07-14 - Kvartalsrapport 2023-Q2
2023-04-28 - Kvartalsrapport 2023-Q1
2023-04-21 - X-dag ordinarie utdelning AKBM 0.00 NOK
2023-04-20 - Årsstämma
2023-02-15 - Bokslutskommuniké 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-04-29 - Kvartalsrapport 2022-Q1
2022-04-21 - X-dag ordinarie utdelning AKBM 0.00 NOK
2022-04-20 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021
2021-10-29 - Kvartalsrapport 2021-Q3
2021-07-14 - Kvartalsrapport 2021-Q2
2021-04-29 - Kvartalsrapport 2021-Q1
2021-03-15 - X-dag ordinarie utdelning AKBM 0.00 NOK
2021-03-12 - Årsstämma
2021-02-16 - Bokslutskommuniké 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-07-15 - Kvartalsrapport 2020-Q2

Beskrivning

LandNorge
ListaOB Match
SektorHandel & varor
IndustriDagligvaror
Aker BioMarine är verksamma inom bioteknik. Bolaget är specialiserade inom utveckling av kostillskott. Produktportföljen är bred och inkluderar exempelvis omega-3 olja, näringstillskott för djur, samt proteintillskott för fiskeodling. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Kunderna består av både privata aktörer samt grossister. Aker BioMarine grundades år 2006 och har sitt huvudkontor i Oslo.
2023-04-26 11:20:00
26 April 2023: The Korean Ministry of Food and Drug Safety (MFDS) recently held
a hearing regarding the potential grant of approval for Superba krill oil as
Health Functional Food in South Korea. Aker BioMarine has reason to believe
approval for Superba krill oil as Health Functional Food in South Korea will be
received. The formal documentation of the approval can be expected within 15
working days. Upon receipt of the documentation, the company and its local
partner will reinitiate marketing and sales in the country.

In South Korea, krill oil has been one of the most successful health-functional
foods the last years. However, due to overly aggressive marketing and
low-quality products from unserious suppliers, the Ministry of Food and Drug
Safety (MFDS) tightened the regulation of the krill oil category in late 2020,
effectively blocking all sales of krill oil products in the country.

The new regulations require krill oil products to undergo more rigorous testing
and labeling requirements to ensure their safety and efficacy. This move is
expected to restore consumer confidence in the krill oil market and promote the
development of high-quality products.

An approval is based on a review of the company's manufacturing process, the
product characteristics, and conducted scientific studies, and will be exclusive
to Superba krill oil.

"The South Korean market for krill oil has historically been important for Aker
BioMarine, and in 2019 and 2020, it accounted for around 25% of our Superba
krill oil sales. We welcomed the tightening of regulations for the krill oil
category as the market had attracted less serious suppliers and products which
did not live up to their health claims. With approval of our high-quality
Superba krill oil as Health Functional Food, we will re-launch marketing and
sales in the South Korean market together with our long-term local partner. We
expect new marketing campaigns to start towards the end of the second quarter,
and gradually lift sales through 2023 and 2024.", said Matts Johansen, CEO of
Aker BioMarine.

For further information, please contact
Katrine Klaveness, CFO
Mobile: +47 991 58 915
Email: Katrine.Klaveness@akerbiomarine.com

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Lars Jacobsen, General Counsel, on 26 April, at
11:19 CET.

About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for pharma, consumer health and
wellness as well as animal nutrition. The company has a strong position in its
industry and is the world's leading supplier of krill, the natural, powerful and
health-promoting source of nutrients from the pristine waters of Antarctica.
Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is
available at www.akerbiomarine.com.